Chart: Recent And Upcoming FDA Advisory Meetings

Recent And Upcoming FDA Advisory Meetings
Topic	Advisory Committee	Date
Genzyme's Clolar (clofarabine) injection for added indication of acute myeloid leukemia in patients over age 60 with at least one unfavorable prognostic factor; Vion's Onrigin (laromustine) injection for remission induction in patients over 60 with de novo poor-risk AML	Oncologic Drugs	Sept. 1
Gloucester's Istodax (romidepsin) for cutaneous T-cell lymphoma, including relief of pruritus; Allos Therapeutics' Folotyn (pralatrexate) for relapsed or refractory peripheral T-cell lymphoma	Oncologic Drugs	Sept. 2
GlaxoSmithKline's Human Papillomavirus vaccine for use in females, and Merck's HPV vaccine Gardasil for use in males	Vaccines and Related Biological Products	Sept. 9
Auxilium Pharmaceuticals' BLA for clostridial collagenase for advanced Dupuytren's disease	Arthritis Drugs	Sept. 16
Neuromed's Exalgo (modified-release hydromorphone) for moderate to severe pain in opioid-tolerant patients	Anesthetic Life Support Drugs and Drug Safety and Risk Management	Sept. 23
Discussion of new data for Purdue's Oxycontin (oxycodone controlled-release) tablets for moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time	Anesthetic Life Support Drugs and Drug Safety and Risk Management	Sept. 24
Schering Plough's PegIntron (peginterferon alfa-2b) as an adjuvant to surgery for metastatic melanoma, and GlaxoSmithKline's Amala (pazopanib) for advanced renal cell carcinoma	Oncologic Drugs	Oct. 5
ApoPharma's Ferriprox (deferiprone) as an iron chelating agent to treat iron overload or build-up in patients with transfusion-dependent thalassemia or other transfusion-dependent anemias	Oncologic Drugs	Oct. 6
Pfizer's Selzentry (maraviroc) for supplemental indication to treat antiretroviral-naïve patients with chemokine (c-c motif) receptor 5 (CCR5) tropic human immunodeficiency virus	Antiviral Drugs	Oct. 8
Acorda Therapeutics' Amaya (fampidine-SR) to improve walking ability in multiple sclerosis patients	Peripheral and Central Nervous System Drugs	Oct. 14